Targeted therapy use in melanoma has been extended beyond just metastatic disease to now include adjuvant therapy for patients with resected stage III melanoma.
Archive | Clinical Trials
Adjuvant Targeted Therapy Proves Beneficial in Resected Stage III BRAF-Mutant Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
mRNA-based therapeutic cancer vaccine enters Phase II trial
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo® (cemiplimab) for the treatment of melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer
The combination of the galactin-3 inhibitor belapectin (GR-MD-02) plus pembrolizumab (Keytruda) has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma…
Posted in Melanoma News, Health Professionals, Clinical Trials
Novel Immunotherapy Combination Produces Durable Response in Untreated Metastatic Melanoma
An unmet need remains for novel immune checkpoint inhibitor combinations that achieve durable and deep responses in patients with metastatic melanoma, without adding substantial toxicity.
Posted in Melanoma News, Health Professionals, Clinical Trials
